Luigi Secchi
38.4K posts
@SecchiLuigi
'Ciò che il gregge odia di più è chi la pensa diversamente; non è tanto l'opinione in sé ma l'audacia di pensare da sé, qualcosa che essi non sanno fare.'
Does anyone else find it odd that $200 billion is spent on cancer research every single year and the only thing to show for it is a 75% increase in cancer deaths since the 1990s?
Most Promising Molecules that Fight Alzheimer’s (New Science) 1/12) Here are five molecules that might protect the brain against Alzheimer’s based on new 2025 – 2026 science. Lock in. This one goes deep!
It feels very futuristic to imagine a world with one-and-done therapies that lower LDL cholesterol for life, but... it might not be far off! These are new phase 1 data for Verve/Lilly's PCSK9 base editor: one single intravenous infusion reduces LDL cholesterol by as much as 60%
@AmmousMD My husband 65 was prescribed rosuvastatin by his GP and after some time his kidney function plummeted to 42. I took him off this drug and after a year his function recovered to 85. My GP must have known about this correlation. I have no trust in my GP anymore...
Masks show no detectable benefit (only harm)
Would you permanently edit the DNA of cells in your liver in order to lower your LDL cholesterol and your risk of a heart attack? Eli Lilly spent $1 billion a year ago to Verve Therapeutics, a company founded by cardiologist and geneticist @skathire on just that idea. This morning early data on the company's new experimental gene editor were published in the New England Journal of Medicine and presented at the annual meeting of the European Atherosclerosis Society in Athens. The treatment lowered LDL, which we know causes heart attacks, by 62% -- about the same amount as 10 mg of rosuvastatin plus ezetimibe. But Kathiresan points out to my colleague Jason Mast that constant LDL-lowering should work better than a pill patients often stop taking. “I treated patients for about 20 years, and you know, patients ask me all the time whether they’ll be on cholesterol medicine for the rest of their lives,” Kathiresan said. “And I think with VERVE-102 for the first time, I can tell them maybe not.” Cardiologists say it will take time, data, and experience to know if this approach is right for some people. There were no treatment-related serious adverse events in the Phase 1 study — a notable finding, given that Verve had to shelve its first candidate due to safety concerns.
